You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Bid

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Helicobacter Pylori Infection, Helicobacter Pylori Infection, Susceptibility to Trial in Karachi (Sequential Regimen:

Completed
  • Helicobacter Pylori Infection
  • Helicobacter Pylori Infection, Susceptibility to
  • Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID
  • Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID
  • Karachi, Sindh, Pakistan
    Jamal Noor Hospital, Karachi
May 8, 2023

Hyperphosphatemia Patients on Hemodialysis Trial in Tokyo (TS-172 10mg bid, TS-172 30mg bid, TS-172 60mg bid)

Not yet recruiting
  • Hyperphosphatemia Patients on Hemodialysis
  • TS-172 10mg bid
  • +4 more
  • Tokyo, Japan
    Taisho Pharmaceutical Co., Ltd selected site
Jan 23, 2023

Post-menopausal Vasomotor Symptoms Trial in West Bend (ACER-801 50 mg BID, ACER-801 100 mg BID, ACER-801 200 mg BID)

Recruiting
  • Post-menopausal Vasomotor Symptoms
  • ACER-801 50 mg BID
  • +3 more
  • West Bend, Wisconsin
    Spaulding Clinical Research
Jan 30, 2023

Atopic Dermatitis Trial in Boston (Apremilast)

Recruiting
  • Atopic Dermatitis
  • Boston, Massachusetts
    Tufts Medical Center, Department of Dermatology
Jul 1, 2022

Inhibition of Autophagy Synergizes Anti-tumor Effect Trial in Guangzhou (100mg bid dose of hydroxychloroquine combined with

Recruiting
  • Inhibition of Autophagy Synergizes Anti-tumor Effect
  • 100mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
  • RP2D dose of 100mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jul 19, 2023

Diabetic Peripheral Neuropathic Pain Trial in Luoyang (HSK16149 20mg BID)

Recruiting
  • Diabetic Peripheral Neuropathic Pain
  • HSK16149 20mg BID
  • Luoyang, Henan, China
    The First Affiliated Hospital of Henan University of Science and
Nov 2, 2023

Beta-Thalassemia Trial in Bulgaria, Israel, United States (VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID)

Withdrawn
  • Beta-Thalassemia
  • VIT-2763 60 mg QD
  • +3 more
  • Whittier, California
  • +6 more
Nov 7, 2022

Asthma Trial (mometasone furoate combination MDI 200/10 mcg BID, mometasone furoate combination MDI 400/10 mcg BID,

Completed
Has Results
  • Asthma
  • mometasone furoate combination MDI 200/10 mcg BID
  • +3 more
  • (no location specified)
Feb 7, 2022

Herpetic Neuralgia Trial in Wuhan (HSK16149 20mg BID, HSK16149 40mg BID, Pregabalin 150mg)

Recruiting
  • Herpetic Neuralgia
  • HSK16149 20mg BID
  • +2 more
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Feb 28, 2023

Plaque Psoriasis Trial (apremilast, Placebo)

Not yet recruiting
  • Plaque Psoriasis
  • (no location specified)
Nov 3, 2023

Advanced Solid Tumors, HER2-positive Breast Cancer Trial in United States (ZN-A-1041 50mg BID, ZN-A-1041 100mg BID, ZN-A-1041

Recruiting
  • Advanced Solid Tumors
  • HER2-positive Breast Cancer
  • ZN-A-1041 50mg BID
  • +12 more
  • Tucson, Arizona
  • +6 more
Nov 16, 2022

Malignant Solid Tumors Trial in France (Nilotinib (400 mg BID), Everolimus (10 mg QD), Sorafenib (400 mg BID))

Recruiting
  • Malignant Solid Neoplasms
  • Nilotinib (400 mg BID)
  • +6 more
  • Bordeaux, France
  • +6 more
Dec 15, 2022

Helicobacter Pylori Infection Trial in Kaohsiung (10d bismuth quadruple therapy, 14d hybrid therapy, 14D high-dose dual therapy)

Recruiting
  • Helicobacter Pylori Infection
  • 10d bismuth quadruple therapy
  • +2 more
  • Kaohsiung, Taiwan
    Kaohsiung Veterans General Hospital
Mar 11, 2022

The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA Trial (Ruxolitinib 5 MG BID Oral Tablet)

Not yet recruiting
  • The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
  • Ruxolitinib 5 MG BID Oral Tablet
  • (no location specified)
Jun 13, 2023

Healthy Subjects Trial in Geelong, Melbourne (JT001 200mg Bid, JT001 400mg Bid, JT001 600mg Bid)

Not yet recruiting
  • Healthy Subjects
  • JT001 200mg Bid
  • +2 more
  • Geelong, Victoria, Australia
  • +1 more
Apr 25, 2022

Fuchs Endothelial Corneal Dystrophy Trial in Indianapolis, Houston (STN1010904 ophthalmic suspension 0.03% BID, STN1010904

Recruiting
  • Fuchs Endothelial Corneal Dystrophy
  • STN1010904 ophthalmic suspension 0.03% BID
  • +2 more
  • Indianapolis, Indiana
  • +7 more
Jan 31, 2023

Healthy Trial in Glendale (Rodatristat Ethyl 300 mg BID, Rodatristat Ethyl 600 mg BID, Placebo)

Completed
  • Healthy
  • Rodatristat Ethyl 300 mg BID
  • +2 more
  • Glendale, California
    California Clinical Trials Medical Group (CCTMG)
Jul 11, 2022

Vascular Ehlers-Danlos Syndrome Trial in Culver City (ACER-002 (celiprolol) 200 mg BID, Placebo BID)

Enrolling by invitation
  • Vascular Ehlers-Danlos Syndrome
  • ACER-002 (celiprolol) 200 mg BID
  • Placebo BID
  • Culver City, California
    Science 37
Aug 12, 2022

Idiopathic Pulmonary Fibrosis Trial in Charleston (DWN12088, Placebo)

Not yet recruiting
  • Idiopathic Pulmonary Fibrosis
  • Charleston, South Carolina
    Daewoong Investigator site
Jul 25, 2022

Androgenetic Alopecia (AGA) Trial in China (KX-826-2.5 mg (0.25%)/60 mL BID, KX-826-5 mg (5%)/60 mL QD, KX-826-5 mg (5%)/60 mL

Completed
  • Androgenetic Alopecia (AGA)
  • KX-826-2.5 mg (0.25%)/60 mL BID
  • +3 more
  • Beijing, Beijing, China
  • +8 more
Jul 17, 2023

Hepatic Impairment Trial (oral dose of 200 mg pacritinib twice daily (BID))

Not yet recruiting
  • Hepatic Impairment
  • oral dose of 200 mg pacritinib twice daily (BID)
  • (no location specified)
Sep 23, 2022

Moderate to Severe COPD (COPD) Trial in Worldwide (CHF1535 + CHF5992 dose 1 BID, CHF1535 + CHF5992 dose2 BID, CHF1535 daily

Completed
  • Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
  • CHF1535 + CHF5992 dose 1 BID
  • +2 more
  • Sofia, Bulgaria
  • +5 more
Oct 28, 2021

Hair in Adult Participants Taking Oral Oriahnn Capsules With

Not yet recruiting
  • Uterine Fibroids (UF)
    • (no location specified)
    Sep 22, 2023

    High Triglycerides Trial (NST-1024, Placebo)

    Not yet recruiting
    • High Triglycerides
    • (no location specified)
    May 25, 2023

    Peripheral Neuropathic Pain Trial in Beijing (HSK16149 40mg BID)

    Active, not recruiting
    • Peripheral Neuropathic Pain
    • HSK16149 40mg BID
    • Beijing, Beijing, China
      Peking University First Hospital
    May 24, 2023